What is already known about this subject:
High interindividual variability in pharmacokinetics coupled with a clear exposure-effect relationship make sunitinib an ideal candidate for therapeutic drug monitoring (TDM).
However, there are no recommendations for the TDM of sunitinib and hence not followed